Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen's Presentations at AASLD 2024: Ipsen showcased data on the long-term efficacy and safety of Bylvay in treating Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille syndrome (ALGS) at the American Association for the Study of Liver Diseases, highlighting sustained improvements in symptoms such as pruritus and serum bile acid levels over 72 weeks.

Commitment to Rare Liver Diseases: The company emphasized its dedication to addressing the challenges faced by patients with PFIC and ALGS, noting the importance of effective management options like Bylvay, which has shown a favorable safety profile and significant benefits for patients.